Author(s)

Bruna de Souza Faustino¹, Alberto dos Reis Costa Junior¹, Letícia Nascimento Medeiros Bortolon¹, Larissa Bianca Paiva Cunha de Sá¹, Denise Rosso Tenório Wanderley Rocha¹, Alberto Krayyem Arbex^1,2

¹Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil.
²Visiting Scientist of the Harvard School of Public Health, Harvard University, Boston, USA.

The sodium and glucose co-transporter inhibitors type 2 (SGLT2) comprises a new class of hypoglycemic drugs to control type 2 diabetes mellitus, in an attempt to add new non-existing benefits to the so far arising classes. Regarding this new class of drugs, represented by dapaglifozin, canaglifozin and empaglifozin, it is important to highlight the benefits brought by these medications to combat hyperglycemia with insulin-independent mechanisms that are beyond glucose reduction, such as cardiovascular events prevention, reduction in HbA1c, weight loss and blood pressure lowering. Recently, a relevant study (Empa-Reg) brought hope and set the spotlight on the prevention of cardiac events among diabetic patients, which is the main cause of mortality within this group. However, despite coming out as a good treatment option, SGLT2 inhibitors are under constant clinical research and, as a new drug, it should be carefully carried out regarding the long-term effects of glycosuria and other possible side effects, such as the observed increase in the incidence of bladder, breast cancer and bone fractures, which require further studies. Therefore, these compounds might represent a landmark approach for the treatment of diabetes.

Diabetes, SGLT-2 Inhibitor, Glycemic Control, Cardiovascular Risk, Empa-Reg, Side Effects, Weight Loss

Faustino, B. , Junior, A. , Bortolon, L. , de Sá, L. , Rocha, D. and Arbex, A. (2016) The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes. Open Journal of Endocrine and Metabolic Diseases, 6, 87-94. doi: 10.4236/ojemd.2016.61012.